Evolution of the treatment of primary central nervous system lymphoma in a Regional Cancer Center of South India: Impact of high-dose methotrexate on treatment outcome
dc.contributor.author | Rudresha, AH | en_US |
dc.contributor.author | Chaudhuri, Tamojit | en_US |
dc.contributor.author | KC, Lakshmaiah | en_US |
dc.contributor.author | Babu, Govind | en_US |
dc.contributor.author | KN, Lokesh | en_US |
dc.contributor.author | LK, Rajeev | en_US |
dc.date.accessioned | 2020-11-18T10:08:16Z | |
dc.date.available | 2020-11-18T10:08:16Z | |
dc.date.issued | 2020-04 | |
dc.description.abstract | Objective: Primary central nervous system lymphoma (PCNSL) is a rare form of aggressive extranodal non-Hodgkin lymphoma. This study attempts to delineate the clinicopathological and radiological profile of PCNSL cases at our center. Materials and Methods: All the pathologically confirmed PCNSL cases between January 2007 and July 2016 were analyzed retrospectively. The influence of potential prognostic parameters and therapeutic strategies on survival was investigated by log-rank test and Cox regression analysis. Results: Of the 53 PCNSL patients, 34 (64%) patients were males. Median age at diagnosis was 44 years (range 22–65 years). The most common location in the brain was the cerebral hemispheres in 32 patients (60%), and 16 patients (30%) had multiple intracranial lesions. Histologically, all patients were diffuse large B-cell lymphomas, except one case of anaplastic large-cell lymphoma. The median survival of the patients received whole-brain radiation alone ( n = 6), standard CHOP chemotherapy + radiation ( n = 14), and DeAngelis protocol ( n = 31) was 8 months, 13 months, and 23 months, respectively. Among the 31 patients treated with DeAngelis protocol, Memorial Sloan Kettering Cancer Center Class 1 ( n = 23) and Class 2 ( n = 8) patients had a median overall survival (OS) of 25 months and 13 months, respectively. The incidence of treatment-related neurotoxicity was significantly higher with DeAngelis protocol, in comparison to CHOP + whole-brain radiation therapy (26% vs. 14%, P < 0.05). Conclusion: None of the potential prognostic factors had a statistically significant influence on OS in our patients. High-dose methotrexate-based chemotherapy combined with radiation was the only factor, which had a significant impact on survival (log-rank P = 0.000) but at the cost of increased neurotoxicity | en_US |
dc.identifier.affiliations | Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India | en_US |
dc.identifier.citation | Rudresha AH, Chaudhuri Tamojit, KC Lakshmaiah, Babu Govind, KN Lokesh, LK Rajeev. Evolution of the treatment of primary central nervous system lymphoma in a Regional Cancer Center of South India: Impact of high-dose methotrexate on treatment outcome. Journal of Cancer Research and Therapeutics. 2020 Apr; 16(1): 13-17 | en_US |
dc.identifier.issn | 0973-1482 | |
dc.identifier.place | India | en_US |
dc.identifier.uri | https://imsear.searo.who.int/handle/123456789/213790 | |
dc.language | en | en_US |
dc.publisher | Wolters Kluwer India Pvt. Ltd. | en_US |
dc.relation.issuenumber | 1 | en_US |
dc.relation.volume | 16 | en_US |
dc.source.uri | https://dx.doi.org//10.4103/0973-1482.204843 | en_US |
dc.subject | Chemotherapy | en_US |
dc.subject | high‑dose methotrexate | en_US |
dc.subject | primary central nervous system lymphoma | en_US |
dc.subject | radiotherapy | en_US |
dc.title | Evolution of the treatment of primary central nervous system lymphoma in a Regional Cancer Center of South India: Impact of high-dose methotrexate on treatment outcome | en_US |
dc.type | Journal Article | en_US |
Files
Original bundle
1 - 1 of 1